Expected Moves

(Driven by VBR) VBR's Q3 2026 earnings and distribution update, providing insights into recent AUM flows and fee-related constituent dividend yields.

(Driven by ADBE) Q3 FY26 results and updated FY26 guidance, with a focus on Digital Media net-new ARR, Experience Cloud momentum, and early monetization of Firefly and other generative AI features.

(Driven by VBR) Full-year 2026 results and Q4 distribution announcement for VBR, setting the baseline yield profile for the new year.

(Driven by JEF) The Capital Return and Balance Sheet Strategy Update will outline the company's plans for returning capital to shareholders and managing its balance sheet. This event is expected to have a high impact as it signals the company's long-term financial health and strategic priorities. Positive guidance may attract institutional investors, while negative signals could lead to short-term sell-offs. The target price is $56.50, with a fallback level of $51.50 if the strategy is viewed unfavorably.

(Driven by SJM) The Q3 2027 earnings release is expected to highlight the company's performance in the seasonal demand period and its ability to leverage pricing power. This event will provide important insights into the company's ability to navigate seasonal fluctuations and maintain profitability. The outcome is likely to have a major impact on the stock's trajectory.

(Driven by VBR) Federal Reserve interest rate decision and its cascading impact on the highly leveraged small-cap value constituents of VBR.

(Driven by VBR) VBR's Q1 2027 earnings and distribution update, reflecting early 2027 AUM stickiness and the health of constituent payout ratios post-FOMC.

(Driven by MCK) Strategic pipeline update following major oncology conferences, evaluating McKesson's exclusive distribution rights for newly commercialized therapies.

(Driven by THC)